Literature DB >> 8031060

Multiple-drug-resistant mutants of feline immunodeficiency virus selected with 2',3'-dideoxyinosine alone and in combination with 3'-azido-3'-deoxythymidine.

J M Gobert1, K M Remington, Y Q Zhu, T W North.   

Abstract

Mutants of feline immunodeficiency virus (FIV) were selected in cell culture in the continuous presence of 10 microM (each) 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxyinosine (ddI). These mutants (AIR-1 and AIR-3) displayed a 13-fold resistance to AZT but had less than a 2-fold decrease in susceptibility to ddI. Interestingly, the AIR mutants were cross-resistant to phosphonoformate (PFA) and were hypersensitive to 2',3'-dideoxycytidine (ddC). Mutants of FIV were also selected in the presence of 10 microM ddI alone (DIS-1, DIS-2c), and these displayed a two- to fourfold decrease in susceptibility to ddI. Like the mutants selected with the combination of AZT plus ddI, DIS-1 and DIS-2c were cross-resistant to PFA and were hypersensitive to ddC. However, they remained as susceptible as wild-type FIV to AZT. Thus, the mutants selected with the combination of AZT plus ddI have phenotypes which reflect those obtained by selection with these drugs individually.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8031060      PMCID: PMC284556          DOI: 10.1128/AAC.38.4.861

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Clinical staging of feline immunodeficiency virus infection.

Authors:  T Ishida; I Tomoda
Journal:  Nihon Juigaku Zasshi       Date:  1990-06

2.  Acquired immune dysfunction in cats with experimentally induced feline immunodeficiency virus infection: comparison of short-term and long-term infections.

Authors:  J E Barlough; C D Ackley; J W George; N Levy; R Acevedo; P F Moore; B A Rideout; M D Cooper; N C Pedersen
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1991

3.  Progressive immune dysfunction in cats experimentally infected with feline immunodeficiency virus.

Authors:  M Torten; M Franchini; J E Barlough; J W George; E Mozes; H Lutz; N C Pedersen
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

4.  Feline immunodeficiency virus, a model for reverse transcriptase-targeted chemotherapy for acquired immune deficiency syndrome.

Authors:  T W North; G L North; N C Pedersen
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

5.  Direct comparisons of inhibitor sensitivities of reverse transcriptases from feline and human immunodeficiency viruses.

Authors:  T W North; R C Cronn; K M Remington; R T Tandberg
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

6.  Characterization of reverse transcriptase from feline immunodeficiency virus.

Authors:  T W North; R C Cronn; K M Remington; R T Tandberg; R C Judd
Journal:  J Biol Chem       Date:  1990-03-25       Impact factor: 5.157

7.  Mutants of feline immunodeficiency virus resistant to 3'-azido-3'-deoxythymidine.

Authors:  K M Remington; B Chesebro; K Wehrly; N C Pedersen; T W North
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

8.  Pathogenesis of experimentally induced feline immunodeficiency virus infection in cats.

Authors:  J K Yamamoto; E Sparger; E W Ho; P R Andersen; T P O'Connor; C P Mandell; L Lowenstine; R Munn; N C Pedersen
Journal:  Am J Vet Res       Date:  1988-08       Impact factor: 1.156

9.  Immunologic abnormalities in pathogen-free cats experimentally infected with feline immunodeficiency virus.

Authors:  C D Ackley; J K Yamamoto; N Levy; N C Pedersen; M D Cooper
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

10.  Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome.

Authors:  N C Pedersen; E W Ho; M L Brown; J K Yamamoto
Journal:  Science       Date:  1987-02-13       Impact factor: 47.728

View more
  5 in total

1.  A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides.

Authors:  R A Smith; K M Remington; R M Lloyd; R F Schinazi; T W North
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

2.  Mutants of feline immunodeficiency virus resistant to 2',3'-dideoxy-2',3'-didehydrothymidine.

Authors:  Y Q Zhu; K M Remington; T W North
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

3.  A novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (-)-beta-2',3'-dideoxy-3'-thiacytidine and 3'-azido-3'-deoxythymidine.

Authors:  R A Smith; K M Remington; B D Preston; R F Schinazi; T W North
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

4.  Selection and characterization of a mutant of feline immunodeficiency virus resistant to 2',3'-dideoxycytidine.

Authors:  H K Medlin; Y Q Zhu; K M Remington; T R Phillips; T W North
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

Review 5.  Efficacy of Antiviral Drugs against Feline Immunodeficiency Virus.

Authors:  Katrin Hartmann; Anita Wooding; Michèle Bergmann
Journal:  Vet Sci       Date:  2015-12-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.